A phase Ib/II randomized, open-label drug repurposing trial of glutamate signaling inhibitors in combination with chemoradiotherapy in patients with newly diagnosed glioblastoma: the GLUGLIO trial protocol

Abstract Background Glioblastoma is the most common and most aggressive malignant primary brain tumor in adults. Glioblastoma cells synthesize and secrete large quantities of the excitatory neurotransmitter glutamate, driving epilepsy, neuronal death, tumor growth and invasion. Moreover, neuronal ne...

Descripció completa

Dades bibliogràfiques

Autors principals:	Maximilian Mastall, Patrick Roth, Andrea Bink, Angela Fischer Maranta, Heinz Läubli, Andreas Felix Hottinger, Thomas Hundsberger, Denis Migliorini, Adrian Ochsenbein, Katharina Seystahl, Lukas Imbach, Tibor Hortobagyi, Leonhard Held, Michael Weller, Hans-Georg Wirsching
Format:	Artigo
Idioma:	Inglês
Publicat:	BMC 2024-01-01
Col·lecció:	BMC Cancer
Matèries:	Epilepsy Gabapentin Sulfasalazine Memantine Cancer neuroscience
Accés en línia:	https://doi.org/10.1186/s12885-023-11797-z
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!